21(top 1%)
papers
386(top 1%)
citations
11(top 1%)
h-index
17(top 1%)
g-index
34
all documents
410
doc citations
234
citing journals

Top Articles

#TitleJournalYearCitations
1Double-Blind Randomized Trials of Single-Tablet Ibuprofen/High-Dose Famotidine vs. Ibuprofen Alone for Reduction of Gastric and Duodenal UlcersAmerican Journal of Gastroenterology201285
2American Society for Pain Management Nursing Position Statement: Pain Management in Patients with Substance Use DisordersPain Management Nursing201257
3Improving Study Conduct and Data Quality in Clinical Trials of Chronic Pain Treatments: IMMPACT RecommendationsJournal of Pain202037
4Pegloticase Treatment Significantly Decreases Blood Pressure in Patients With Chronic GoutHypertension201931
5Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticaseArthritis Research and Therapy201828
6Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory goutArthritis Research and Therapy201725
7Pharmacokinetics of Modified‐Release Prednisone Tablets in Healthy Subjects and Patients With Rheumatoid ArthritisJournal of Clinical Pharmacology201324
8Delayed-release prednisone improves fatigue and health-related quality of life: findings from the CAPRA-2 double-blind randomised study in rheumatoid arthritisRMD Open201519
9Use of Pre-Infusion Serum Uric Acid Levels as a Biomarker for Infusion Reaction Risk in Patients on PegloticaseRheumatology and Therapy201917
10Overt hepatic encephalopathy: development of a novel clinician reported outcome tool and electronic caregiver diaryMetabolic Brain Disease201616
11The Relative Bioavailability and Effects of Food and Acid‐Reducing Agents on Filgotinib Tablets in Healthy SubjectsClinical Pharmacology in Drug Development201916
12Morning stiffness response with delayed-release prednisone after ineffective course of immediate-release prednisoneScandinavian Journal of Rheumatology201513
13What Is the Relationship Between Morning Symptoms and Measures of Disease Activity in Patients With Rheumatoid Arthritis?Arthritis Care and Research201510
14Characterization of patients with chronic refractory gout who do and do not have clinically apparent tophi and their response to pegloticaseRheumatology20198
15Evaluation of Proposed Criteria for Remission and Evidence‐Based Development of Criteria for Complete Response in Patients With Chronic Refractory GoutACR Open Rheumatology20197
16Filgotinib, a JAK1 Inhibitor, Has No Effect on QT Interval in Healthy SubjectsClinical Pharmacology in Drug Development20207
17Urinary phenylacetylglutamine (U-PAGN) concentration as biomarker for adherence in patients with urea cycle disorders (UCD) treated with glycerol phenylbutyrateMolecular Genetics and Metabolism Reports20156
18AB0876 GOUT CAUSING URATE CARDIAC VEGETATIONS: SUMMARY OF PUBLISHED CASES20193
19THU0416 Rapid tophus resolution in chronic refractory gout patients treated with pegloticase20171
20AB0426 Time to Event Analysis of Patient Reported Morning Stiffness Where Delayed-Release (DR) Prednisone Was Compared To, and Replaced, Immediate Release Prednisone in Rheumatoid Arthritis (RA) Patients Receiving DMARDS over 1 YearAnnals of the Rheumatic Diseases20140
21Response to ‘Inclusion of Placebos and Blinding for Ascending Dose First-in-Human Studies and Other Underpowered Phase 1 studies has not been Justified and on Balance is Not Useful’ by D.A. Parasrampuria and L.Z. BenetBasic and Clinical Pharmacology and Toxicology20150
22THU0448 Characterization of patients with chronic refractory gout who do and do not have clinically apparent tophi: response to pegloticase20170
23Facts Concerning Duexis Prescribing Habits Related to Combination TherapiesJAMA Internal Medicine20170
24THU0438 Lack of predictive value of the NIAID/FAAN criteria to identify subjects with evidence of immune activation after receiving pegloticase for chronic refractory gout20170
25THU0449 Evidence based development of criteria for complete response in patients with chronic refractory gout20170
26AB0892 Progressive clinical benefit in chronic refractory gout patients achieving a persistent urate lowering effect from pegloticase treatment20170
27FRI0237 Pegloticase treatment significantly decreases mean arterial blood pressure in patients with chronic gout20180
28AB0875 GOUT, NOT JUST A DISEASE OF THE FOOT. LITERATURE REVIEW OF SYSTEMIC DEPOSITION OF URATE20190
29OP0051 DEVELOPMENT OF A MULTIVARIABLE IMPROVEMENT MEASURE FOR GOUT20190
30SAT0434 A TRANSIENT DECREASE IN SERUM URATE CHANGES THE CLINICAL TRAJECTORY OF SUBJECTS WITH ADVANCED GOUT20190
31SAT0370 Association of renal dysfunction and development of tophi in subjects with chronic refractory gout and response to treatment with pegloticase20180
32OP0184 The frequency of flares in subjects with chronic refractory gout treated with pegloticase is related to variation in the level of plasma urate20180
33SAT0356 Factors influencing tophus resolution in patients with persistent urate lowering responses to pegloticase20180
34SAT-554 Teprotumumab in Graves' Orbitopathy: Extended Outcome AnalysesJournal of the Endocrine Society20190